Study of Leptin for the Treatment of Hypothalamic Amenorrhea
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00130117|
Recruitment Status : Completed
First Posted : August 15, 2005
Results First Posted : May 17, 2017
Last Update Posted : May 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|Amenorrhea||Drug: r-metHuLeptin Drug: Oral Contraceptive Pills (OCPs) Other: Placebo||Phase 2|
Leptin is a hormone secreted by fat cells under normal conditions and acts in the brain to regulate energy usage and hormone levels. Women with HA who do not have regular periods have low leptin levels and may also have other hormone abnormalities as well as loss of bone density (osteopenia or osteoporosis). This study will evaluate how leptin (a fat cell hormone that normally circulates in the blood) affects bone density, menstrual periods, hormone levels, bone metabolism (how bone forms and turns over), immune function (how well the body can fight infection), metabolic rate (how many calories are used at rest), and overall sense of well-being and appetite in women with HA (i.e. no regular menstrual periods due to low levels of pituitary hormones that regulate estrogen production from the ovary). It will also investigate whether leptin replacement can be used as an adjunct to the current standard of care for HA patients, i.e. OCPs.
Part A is a Randomized, placebo-controlled 36-week study. Part B is an Optional open-label 52-week study. There will also be an optional Reward Sub-study, including healthy controls, designed to investigate leptin's relation to reward processing by collecting participants' brain and behavioral responses to images (e.g., pictures of food vs. non-food). Brain responses will be collected and will also be assessed via functional Magnetic Resonance Imaging (fMRI).
Comparison: Part A = leptin-treated group to placebo-treated group and Part B optional sub study = leptin-treated group to health controls
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||December 2016|
r-metHuLeptin administered subcutaneously.
Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Other Name: metreleptinDrug: Oral Contraceptive Pills (OCPs)
Sprintec taken orally once daily.
Other Name: OCPs
Placebo Comparator: Oral Contraceptive Pills (OCPs)
Drug: Oral Contraceptive Pills (OCPs)
Sprintec taken orally once daily.
Other Name: OCPsOther: Placebo
placebo (no active medication)
- the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks [ Time Frame: 36 weeks ]
- Bone Markers - Ctx and Sclerostin [ Time Frame: 36 weeks ]
- Body Composition BMI [ Time Frame: 36 weeks ]
- Total Body BMD [ Time Frame: 36 weeks ]
- Body Fat [ Time Frame: 36 weeks ]
- Total Body BMD [ Time Frame: 9 months ]
- Lumbar BMD [ Time Frame: 9 months ]
- Radial BMD [ Time Frame: 9 months ]
- Hip BMD [ Time Frame: 9months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00130117
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center General Clinical Research Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Christos S Mantzoros, MD, ScD||Beth Israel Deaconess Medical Center, Harvard Medical School|